https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53632 Wed 28 Feb 2024 16:01:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54338 Wed 28 Feb 2024 15:14:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34787 Wed 19 Jan 2022 15:18:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54592 Wed 15 May 2024 09:23:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27569 Wed 11 Apr 2018 11:56:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37078 Tue 29 Sep 2020 11:48:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36051 Thu 28 Oct 2021 13:04:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24852 Thu 17 Feb 2022 09:28:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49306 Thu 11 May 2023 14:32:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47850 Thu 02 Feb 2023 16:46:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10770 Sat 24 Mar 2018 08:13:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33089 Fri 24 Aug 2018 16:46:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55342 30 mg/d; percent-predicted forced expiratory volume in 1 second [ppFEV1]: <50% to ≥80%). Results: Percentage of biologic responders (ie, those with a category improvement pre- to post-biologic) varied by domain and increased with greater pre-biologic impairment, increasing from 70.2% to 90.0% for exacerbation rate, 46.3% to 52.3% for asthma control, 31.1% to 58.5% for LTOCS daily dose, and 35.8% to 50.6% for ppFEV1. The proportion of patients having improvement post-biologic tended to be greater for anti–IL-5/5R compared with for anti-IgE for exacerbation, asthma control, and ppFEV1 domains, irrespective of pre-biologic impairment. Conclusion: Our results provide realistic outcome-specific post-biologic expectations for both physicians and patients, will be foundational to inform future work on a multidimensional approach to define and assess biologic responders and response, and may enhance appropriate patient selection for biologic therapies. Trial Registration: The ISAR database has ethical approval from the Anonymous Data Ethics Protocols and Transparency (ADEPT) committee (ADEPT0218) and is registered with the European Union Electronic Register of Post-Authorization studies (ENCEPP/DSPP/23720). The study was designed, implemented, and reported in compliance with the European Network Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) Code of Conduct (EUPAS38288) and with all applicable local and international laws and regulation, and registered with ENCEPP (https://www.encepp.eu/encepp/viewResource.htm?id=38289). Governance was provided by ADEPT (registration number: ADEPT1220).]]> Fri 17 May 2024 15:51:09 AEST ]]>